Table 4 Comparisons of baseline characteristics between survivors and non-survivors.
| Â | Survivor (n= 109, 51%) | Non-survivor (n= 105, 49%) | Odds ratio (95% CI) | P value |
|---|---|---|---|---|
Age (years) | 59 (51-66) | 62 (51-69) | 1.007 (0.998-1.027) | 0.477 |
Gender (male) | 71/144 (49) | 73/144 (51) | 1.221 (0.689-2.165) | 0.494 |
Co-morbidity | 51/111 (46) | 60/111 (54) | 1.516 (0.884-2.600) | 0.130 |
Type of malignancy | Â | Â | Â | Â |
   Hematology | 60/115 (52) | 55/115 (48) | 0.898 (0.525-1.538) | 0.696 |
ECOG performance status (3 or more) | 22/61 (36) | 39/61 (64) | 2.337 (1.266-4.313) | 0.006 |
Status of malignancy | Â | Â | Â | Â |
   Relapsed/refractory | 24/64 (38) | 40/64 (63) | 2.179 (1.196-3.973) | 0.010 |
   Extensive or major organ involvement | 76/151 (50) | 75/151 (50) | 1.086 (0.603-1.955) | 0.785 |
   Stem cell transplantation | 9/28 (32) | 19/28 (68) | 2.455 (1.056-5.708) | 0.033 |
   Duration of malignancy, months | 9.8 (3.1-22.5) | 6.9 (2.7-18.4) | 0.997 (0.989-1.005) | 0.486 |
Clinical status on ICU admission | Â | Â | Â | Â |
   Recent chemotherapy | 88/182 (48) | 94/182 (52) | 2.039 (0.930-4.472) | 0.071 |
   Need for mechanical ventilationa | 44/109 (40) | 65.109 (60) | 2.401 (1.386-4.157) | 0.002 |
   Need for vasopressor support | 20/52 (39) | 32/52 (62) | 1.951 (1.030-3.695) | 0.039 |
   Need for renal replacement therapy | 8/19 (42) | 11/19 (58) | 1.477 (0.570-3.832) | 0.42 |
Neutropenia | 12/40 (30) | 28/40 (70) | 2.939 (1.403-6.157) | 0.003 |
Severity of illness | Â | Â | Â | Â |
   SAPS 3 (points) | 59 (50-72) | 64 (50-76) | 1.016 (1.001 - 1.032) | 0.0420 |
   SOFA score (points) | 5 (3-7) | 7 (4-9) | 1.125 (1.033 - 1.226) | 0.007 |
Identified etiology | 96/187 (51) | 91/187 (49) | 0.880 (0.393 - 1.974) | 0.757 |
Therapeutic modification | 61/99 (62) | 38/99 (38) | 0.446 (0.258 - 0.773) | 0.004 |